The immunological era in melanoma treatment: New challenges for heat shock protein-based vaccine in the advanced disease

Alessandra Di Pietro, Giulio Tosti, Pier Francesco Ferrucci, Alessandro Testori

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Tumor-derived heat shock protein (HSP)peptide complexes (HSPPCs) induced immunity against malignancies in preclinical trials, working across tumor types and bypassing the need to identify single immunogenic peptides. These results paved the way for the use of human gp96 obtained from autologous tumor samples as an anti-cancer vaccine. Areas covered: Autologous tumor-derived HSP gp96 peptide complex (HSPPC-96) vaccine is emerging as a tumor- and patient-specific cancer vaccine, with confirmed activity in several malignancies. It has been tested in Phase III clinical trials in advanced melanoma and kidney cancer with evidence for efficacy in patients with earlier stage disease. HSPPC-96-based vaccine demonstrated an excellent safety profile, thus emerging as a novel therapeutic approach with a suggestive role in cancer therapy. This review summarizes work on the use of HSPPC-96 as an autologous anti-tumor vaccine in advanced melanoma. Data were retrieved by PubMed and Medline research and using the authors' personal experience. Expert opinion: Further investigations are needed to understand the biological basis of immune functions in order to improve the clinical outcome of HSP-based cancer therapy. In the near future, the combination of HSP-based vaccines with other biological compounds might represent a successful strategy in the therapy of advanced melanoma.

Original languageEnglish
Pages (from-to)1395-1407
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume11
Issue number10
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Heat-Shock Proteins
Melanoma
Vaccines
Tumors
Peptides
Cancer Vaccines
Neoplasms
Therapeutics
Phase III Clinical Trials
Kidney Neoplasms
Expert Testimony
PubMed
Immunity
Safety
Research

Keywords

  • Gp96
  • Heat shock protein peptide complex
  • Heat shock proteins
  • HSP
  • HSPC4
  • HSPPC
  • HSPPC-96
  • Immunotherapy
  • Melanoma
  • Oncophage
  • Prophage
  • Vaccine
  • Vitespen

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

The immunological era in melanoma treatment : New challenges for heat shock protein-based vaccine in the advanced disease. / Di Pietro, Alessandra; Tosti, Giulio; Ferrucci, Pier Francesco; Testori, Alessandro.

In: Expert Opinion on Biological Therapy, Vol. 11, No. 10, 10.2011, p. 1395-1407.

Research output: Contribution to journalArticle

@article{0e7aca3348d4431b91f66f3837fe62ef,
title = "The immunological era in melanoma treatment: New challenges for heat shock protein-based vaccine in the advanced disease",
abstract = "Introduction: Tumor-derived heat shock protein (HSP)peptide complexes (HSPPCs) induced immunity against malignancies in preclinical trials, working across tumor types and bypassing the need to identify single immunogenic peptides. These results paved the way for the use of human gp96 obtained from autologous tumor samples as an anti-cancer vaccine. Areas covered: Autologous tumor-derived HSP gp96 peptide complex (HSPPC-96) vaccine is emerging as a tumor- and patient-specific cancer vaccine, with confirmed activity in several malignancies. It has been tested in Phase III clinical trials in advanced melanoma and kidney cancer with evidence for efficacy in patients with earlier stage disease. HSPPC-96-based vaccine demonstrated an excellent safety profile, thus emerging as a novel therapeutic approach with a suggestive role in cancer therapy. This review summarizes work on the use of HSPPC-96 as an autologous anti-tumor vaccine in advanced melanoma. Data were retrieved by PubMed and Medline research and using the authors' personal experience. Expert opinion: Further investigations are needed to understand the biological basis of immune functions in order to improve the clinical outcome of HSP-based cancer therapy. In the near future, the combination of HSP-based vaccines with other biological compounds might represent a successful strategy in the therapy of advanced melanoma.",
keywords = "Gp96, Heat shock protein peptide complex, Heat shock proteins, HSP, HSPC4, HSPPC, HSPPC-96, Immunotherapy, Melanoma, Oncophage, Prophage, Vaccine, Vitespen",
author = "{Di Pietro}, Alessandra and Giulio Tosti and Ferrucci, {Pier Francesco} and Alessandro Testori",
year = "2011",
month = "10",
doi = "10.1517/14712598.2011.605353",
language = "English",
volume = "11",
pages = "1395--1407",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - The immunological era in melanoma treatment

T2 - New challenges for heat shock protein-based vaccine in the advanced disease

AU - Di Pietro, Alessandra

AU - Tosti, Giulio

AU - Ferrucci, Pier Francesco

AU - Testori, Alessandro

PY - 2011/10

Y1 - 2011/10

N2 - Introduction: Tumor-derived heat shock protein (HSP)peptide complexes (HSPPCs) induced immunity against malignancies in preclinical trials, working across tumor types and bypassing the need to identify single immunogenic peptides. These results paved the way for the use of human gp96 obtained from autologous tumor samples as an anti-cancer vaccine. Areas covered: Autologous tumor-derived HSP gp96 peptide complex (HSPPC-96) vaccine is emerging as a tumor- and patient-specific cancer vaccine, with confirmed activity in several malignancies. It has been tested in Phase III clinical trials in advanced melanoma and kidney cancer with evidence for efficacy in patients with earlier stage disease. HSPPC-96-based vaccine demonstrated an excellent safety profile, thus emerging as a novel therapeutic approach with a suggestive role in cancer therapy. This review summarizes work on the use of HSPPC-96 as an autologous anti-tumor vaccine in advanced melanoma. Data were retrieved by PubMed and Medline research and using the authors' personal experience. Expert opinion: Further investigations are needed to understand the biological basis of immune functions in order to improve the clinical outcome of HSP-based cancer therapy. In the near future, the combination of HSP-based vaccines with other biological compounds might represent a successful strategy in the therapy of advanced melanoma.

AB - Introduction: Tumor-derived heat shock protein (HSP)peptide complexes (HSPPCs) induced immunity against malignancies in preclinical trials, working across tumor types and bypassing the need to identify single immunogenic peptides. These results paved the way for the use of human gp96 obtained from autologous tumor samples as an anti-cancer vaccine. Areas covered: Autologous tumor-derived HSP gp96 peptide complex (HSPPC-96) vaccine is emerging as a tumor- and patient-specific cancer vaccine, with confirmed activity in several malignancies. It has been tested in Phase III clinical trials in advanced melanoma and kidney cancer with evidence for efficacy in patients with earlier stage disease. HSPPC-96-based vaccine demonstrated an excellent safety profile, thus emerging as a novel therapeutic approach with a suggestive role in cancer therapy. This review summarizes work on the use of HSPPC-96 as an autologous anti-tumor vaccine in advanced melanoma. Data were retrieved by PubMed and Medline research and using the authors' personal experience. Expert opinion: Further investigations are needed to understand the biological basis of immune functions in order to improve the clinical outcome of HSP-based cancer therapy. In the near future, the combination of HSP-based vaccines with other biological compounds might represent a successful strategy in the therapy of advanced melanoma.

KW - Gp96

KW - Heat shock protein peptide complex

KW - Heat shock proteins

KW - HSP

KW - HSPC4

KW - HSPPC

KW - HSPPC-96

KW - Immunotherapy

KW - Melanoma

KW - Oncophage

KW - Prophage

KW - Vaccine

KW - Vitespen

UR - http://www.scopus.com/inward/record.url?scp=80052438963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052438963&partnerID=8YFLogxK

U2 - 10.1517/14712598.2011.605353

DO - 10.1517/14712598.2011.605353

M3 - Article

C2 - 21801084

AN - SCOPUS:80052438963

VL - 11

SP - 1395

EP - 1407

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -